Mergers and acquisitions are occurring in response to a change environment where organizations are trying to deliver a more comprehensive service, explained Dan Mendelson, MPP, founder, Avalere Health.
Mergers and acquisitions are occurring in response to a change environment where organizations are trying to deliver a more comprehensive service, explained Dan Mendelson, MPP, founder, Avalere Health.
Transcript
How are mergers and acquisitions affecting the market, and do you think this is where the future of healthcare is headed?
Mergers and acquisitions really stem out of this change environment, and you see really the larger organizations—CVS, Aetna, and the like—responding to this change environment. They’re trying to figure out how do we deliver a more comprehensive service offering that really accomplishes what government and other major payers want us to deliver. So, to me this is really fundamental for retail pharmacy. Now, retail pharmacy has not been a bright spot economically, really, for anyone operating it, and that’s not secret.
So, reinventing the pharmacy and kind of reimagining what can be done in that context to engage patients is really important, and I think that we are likely to see a lot of M&A activity that is really focused around that so the idea of a combination of health plan and a drug store, for example, kind of speaks to that.
Then, we have some mergers and acquisitions that are just about creating scale, just getting larger. And if you get larger, you can reduce your cost basis and be a more effective player in the marketplace. So, we will continue to see that both in the pharmacy area, as well as in the health plan area, as well as in the provider area. A lot of activity, we expect it really to continue. In fact, it might even intensify over time as the demands of the payers become a bit more strenuous.
Could On-Body Delivery of Isatuximab Bring More Competition to Anti-CD38 Myeloma Treatment?
June 6th 2025Results for IRAKLIA show noninferiority for Sanofi's on-body delivery system for isatuximab, compared with IV administration. Patients overwhelmingly preferred the hands-free delivery option.
Read More
The Importance of Examining and Preventing Atrial Fibrillation
August 29th 2023At this year’s American Society for Preventive Cardiology Congress on CVD Prevention, Emelia J. Benjamin, MD, ScM, delivered the Honorary Fellow Award Lecture, “The Imperative to Focus on the Prevention of Atrial Fibrillation,” as the recipient of this year’s Honorary Fellow of the American Society for Preventive Cardiology award.
Listen
Zanubrutinib Shows Durable Benefit for High-Risk CLL/SLL at 5 Years in SEQUOIA Trial
June 6th 2025Zanubrutinib showed long-term efficacy in patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) and deletion of the 17p chromosome, with progression-free survival similar to patients without high-risk disease characteristics.
Read More
Promoting Equity in Public Health: Policy, Investment, and Community Engagement Solutions
June 28th 2022On this episode of Managed Care Cast, we speak with Georges C. Benjamin, MD, executive director of the American Public Health Association, on the core takeaways of his keynote session at AHIP 2022 on public health policy and other solutions to promote equitable health and well-being.
Listen
Real-World Data Support Luspatercept vs ESAs for Anemia in Lower-Risk MDS
June 5th 2025Patients with myelodysplastic syndrome (MDS) who received luspatercept showed greater hemoglobin gains and transfusion independence compared with erythropoiesis-stimulating agents (ESAs) in a real-world analysis.
Read More
At EHA 2025, Hematology Discussions Will Stretch Across Lifespans and Locations
June 5th 2025The 2025 European Hematology Association (EHA) Congress, convening virtually and in Milan, Italy, from June 12 to June 15, 2025, will feature a revamped program structure for the meeting’s 30th anniversary while maintaining ample opportunities to network, debate, and absorb practice-changing findings in hematology and oncology.
Read More